Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Dr. Richard Pazdur retires creating oncology approval void, US-UK 0% pharma tariffs officially implemented, Regeneron commits $150M to Tessera gene writing, IQVIA partners with AWS
U.S.-UK eliminate medicine tariffs, Abbott acquires Exact Sciences for $21 billion, FDA signals stricter vaccine approvals, Otsuka wins accelerated kidney nod, and AI infrastructure gains
Zydus-RK Pharma license supportive care injectable, biomimetics market forecast to reach $73.6B by 2034, and Hong Kong approves IASO Bio’s CAR-T as device quality vigilance
FDA approves first gene-replacement therapy for SMA patients 2+ years as Abbott’s 3-million sensor correction exposes fundamental questions about CGM accuracy and post-market surveillance The
Abbott’s global CGM correction intensifies regulatory scrutiny while Novartis extends Itvisma to older SMA patients and CytomX signals renewed ADC momentum November 25, 2025 encapsulated
Novartis extends SMA gene therapy beyond infancy while Abbott’s 3-million-unit sensor correction triggers industry-wide accuracy scrutiny Today marked a pivotal intersection of breakthrough and caution
Abbott acquires Exact Sciences for ~$21B equity, $23B enterprise value in landmark diagnostics deal; Cologuard and Oncotype DX franchises reshape Abbott’s cancer screening footprint; diagnostics-AI
FDA Approvals in HER2-Mutated Lung Cancer and Rare Disease Expand Treatment Arsenal While AI Investment Surges and Medtech Innovation Accelerates An exhaustive examination of regulatory
FDA approves Arrowhead’s plozasiran for ultra-rare FCS; expands epcoritamab in follicular lymphoma; Medtronic raises guidance on >300% PFA growth breaking $100 share price; GLP-1 pricing
Johnson & Johnson’s $3.05B Halda acquisition secures RiPTAC platform; FDA approves first interchangeable Perjeta biosimilar; Nuvalent’s ALK inhibitor delivers pivotal durability; NIH grant terminations disrupt
